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Summary: The performance characteristics and diagnostic value of a monoclonal antibody-based radioimmu-
noassay for serum total thyroxine (Mallinckrodt) are described. Between-batch precision (coefficient of Varia-
tion) was 10.4% at 87 nmol/1 and 3.3% at 185 nmolA Scatchard analysis revealed a linear plot with a Ka of
5.4 x 108 1/mol.
\
Sensitivity was 4.5 nmol/1 of thyroxine. An association study showed that the assay reached equilibrium well
within the specified incubation time. Cross-reaction of triiodothyronine and reverse triiodothyronine in the
assay was 0.6% and 25.0% respectively. Analytical recovery was 91—110%. Linearity was well demonstrated
but dilutions of a high concentration of thyroxine in serum did not parallel the Standard curve. The correlation
coefficient for comparison with a polyclonal antibody assay was 0.95 for 83 patients. The diagnostic accuracy
of the monoclonal antibody assay was adequate for most patients with thyroid disease, pregnant women, oral
contraceptive users and subjects on thyroxine-replacement therapy. Measurement of total thyroxine by a
monoclonal antibody-based method shows no definite advantage over the conventional polyclonal antibody
assay.
Erfahrungen in Laboratorium und Klinik mit einem Radioimmunassay für das gesamte Thyroxin im Serum auf
der Grundlage eines monoklonalen Antikörpers
Zusammenfassung: Die Charäkteristika der Durchführung und der diagnostische Wert eines Radioimmunas-
say mit monoklonalem Antikörper für das gesamte Thyroxin im Serum (Mallinckrodt) werden beschrieben.
Die Impräzision von Serie zu Serie beträgt als Variationskoeffizient 10,4% bei 87 nmol/1 und 3,3% bei 185
nmol/1. Die Scatchard-Analyse ergab einen linearen Verlauf mit einem Wert für Ka von 5,4 x 108 1/mol.
Die Empfindlichkeit betrug 4,5 nmol/1 Thyroxin. Eine Bindungsstudie ergab, daß das Gleichgewicht inner-
halb der angegebenen Inkubationszeit völlig erreicht wird. Die Kreuzreaktionen von Triiodthyronin und re-
verse Triiodthyronin betrugen 0,6 bzw. 25,0%. Die analytische Wiederfindung betrug 91—110%. Es konnte
völlige Linearität nachgewiesen werden, jedoch ergaben Verdünnungen einer hohen Konzentration von Thy-
roxin im Serum keinen parallelen -Verlauf mit der Standardkurve. Der Korrelationskoeffizient für ein Ver-
gleichsverfahren mit polykloiiälem Antikörper betrug r = 0,95 (n = 83 Patienten). Die diagnostische Richtig-
keit des Radioimmunassay mit monoklonalem Antikörper war für die meisten Patienten mit Schilddrüsener-
krankungen, für Frauen* die orale Kontraceptiva einnahmen oder schwanger waren, sowie Personen unter
Thyroxin^Substitution genügend. Die Bestimmung des Gesamtthyroxins unter Verwendung eines monoklo-
nalen Antikörpers zeigt keinen deutlichen Vorteil gegenüber der Verwendung konventioneller polyklonaler
Antikörper.
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Introduction
Monoclonal antibodies, produced by classical hybri-
doma techniques (l, 2) offer several advantages for
the purposes of radioimmunoassay (RIA), namely
monospecificity and elimination of the bleed-to-
bleed Variation which is associated with animal anti-
sera (3, 4). Commercial assay kits, using monoclonal
antibody technology, have achieved relatively wide
use in the estimation of hormones such äs thyrotrop-
in and chorionic gonadotropin because assays em-
ploying classical polyclonal antisera to these hor-
mones display predictable cross-reaction with struc-
turally-related molecules (5). However the role of
monoclonal antibody technology in the assay of a
hormone such äs total thyroxine (T4) is uncertain äs
there are already a large number of excellent com-
mercial kits, utilizing polyclonal antisera, available
for this purpose (6, 7).
The aim of this present study was to examine the
value of using ä monoclonal antibody System for the
estimation of T4 by comparing the laboratory and
clinical performance of the new monoclonal anti-
body sectionally processed coated tube (SPAC) total
T4 kit from Mallinckrodt with that of a well estab-
lished conventional T4 assay (Amerlex: Amersham
International) (8, 9).
Materials and Methods
All sera were assayed for total T4, triiodpthyronine (T3) uptake
ratio, free T4 (FT4) and T3, and the free thyroxine index (FTI);
computed by multiplying the T4 concentration by the T3 uptake
ratio. Reference intervals, for all of these parameters, were deter-
mined in our laboratory.
T4 was determined by the Amerlex (Amersham International
Ltd., Amersham, Bucks, U.K.) and the MCA (SPAC) T4 (Immu-
noassay Systems, Mallinckrodt, Inc. St. Louis, MO 63134) RIA
kits. FT4 and T3 were measured with Amerlex RIA kits (Amer-
sham International) and T3 uptake was estimated with the MAA
kit (Amersham International).
Within-batch precision of the T4 kits was evaluated by assaying
three different concentrations of a lyophilized control material 20
times in a single batch (Ortho tri-level ligand assay control, lot no.
LIGX01; Ortho Diagnostics Systems, Inc., Raritan, NJ 08869).
Between-batch precision was assessed by testing three concentra-
tions of ligand once per day for seven days.
Sensitivity is defined in this study äs the 'minimal detection limit'
of an assay (10). It was characterised, for each T4 assay, by using
20 replicates of a zero calibrator to calculate the concentration
which corresponds to the value for counts per minute that is two
Standard deviations from the mean.
An association study was performed, with low, normal and high
T4 concentration sera, to determine the time needed for the reac-
tants to reach equilibrium.
The specificity of the antibody in each T4 kit was studied by com-
paring the molar ratio (expressed äs a percentage) between the
quantity of T4 and the quantity of the structurally related thyroid
hormones (T3 and reverse T3 (rT3)) which cause 50% displace-
ment of the T4 tracer. T4 and T3 were obtained from the Sigma
Chemical Company and rT3 from Henning Berlin.
Recovery was studied by assaying aliquots of the same hypothy-
roid sample to which were added known and increasing amounts
of T4 Standard. Recoveries were then calculated, äs percentages,
from the quotient of observed and calculated T4 concentration.
Parallelism and linearity were determined by assaying dilutions of
a high concentration of T4 in serum with a buffer solution contain-
ing, per litre, l g of bovine serum albumin, 150 mmol of NaCl,
and 67 mmol of phosphate buffer, pH 7.3^.
Patients
Thyroid Status was determined using assays of serum FT4, fol-
lowed by assays of serum T3 or thyrotropin (TSH) where approp-
riate. Subjects were then classified according to biochemical and
clinical findings äs follows:
Euthyroid controls: Fifty three healthy hospital and laboratory
staff (20 men, 33 women).
Patients wiih thyroid disease: Fifteen hyperthyroid patients (4
men, 1 1 women) were all clinically hyperthyroid and had FT4 corn
centrations > 20 pmol/ and T3 concentrations > 2.5 nmol/l. Fif-
teen hypothyroid patients (2 men, 13 women) were all clinically
hypothyroid and had FT4 concentrations <10 pmpl/l and thyro-
tropin levels >6 iiiU/1, T3 values were within normal limits in nifte
hypothyroid patients.
Euthyroid subjects with increases in thyroxine^binding globulin
(TBC) binding capacity: Third trimester pregnancy: 20 women
(gestational age ränge 30—39 weeks). Contraceptive pill users: 20
women.
Patients on thyroxine^replacement therapy: 20 patients (2 men, 18
women). All patients were clinically controlled on thyroxine and
had. normal FT4 concentrations.
Statistical analysis
The F-test was used for comparison of precision between the two
methods anälysed, Student's paired t-test for comparison of values
between both T4 kits, and Pearson's correlation coefficient (r) to
show the degree of linear association among the different varia-
bles. Further statistical analyses included Studenfs t-statistics for
tests on regression coefficients (11) and the unpaired t-test for
comparing means of different determinations with normal control
mean values, for the various groups under study. A p value of




The within^batch and between-batch precision for
Amerlex and MCA (SPAC) T4 kits is shown in table
1. The performance of the Amerlex kit at three dif-
ferent concentrations was judged to be acceptable
according to the criteria of Tanks (12), i.e. twice the
coefficient of Variation (CV) should be <20%,
whereas the between-batch preeision for the MCA
(SPAC) T4 kit was >10% at low and normal concen-
trations of T4. These variations were higher than
those reported in several studies (8, 13) but similar
to others (6, 7). However over the ränge of concen-
trations studies, there was no statistical difference in
precision between the two methoc^ (F-test). The ob-
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served difference in precision between methods most
likely arises from the inherent problems of coated-
tube technology (10,14) rather than from the nature
of the reagents such äs antibody type.
Tab. l. Within-batch and between-batch precision of 7*4 kits äs
























































Scatchard analysis (15), performed on data con-
tained in the Standard curve, revealed a curvilinear
plot with the Amerlex antibody, indicating multiple
antigenic binding sites. The calculated average affin-
ity constant (Ka) was 6.7 x 1081/mol. By comparison
the monoclonal antibody produced a linear Scat-
chard plot, indicating a single binding site. The cal-
culated Ka of 5.4 x l O81/mol was comparable with a
previous report for this antibody (4). The Ka values
for both antibodies were similar to those reported in
other RIA T4 kits (6, 7). Although the calculated Ka
value for the Amerlex antibody was slightjy higher
than that of the monoclonal antibody, both were of
sufficiently high affinity to provide assays with sensi-
tivities greater than necessary for determination of
serum T4 (minimal detectable dose for Amerlex T4
and MCA (SPAC) T4 were 1.5 nmol/1 and 4.5
nmol/1 respectively).
Association studies showed that the MCA (SPAC) T4
method reached virtüal equilibrium in the specified
incubation tiine (one hour) at the three .different T4
concentrations studiedi, whereas Amerlex achieved
equilibrium befpre 45 minutes (stated incubation
time), only at a high T4 concentration. Amerlex reac-
tions proceeded for two hours without reaching
equilibrium at normal and low T4 concentrations.
Intermethod comparison
Using 83 serum sanjples, there was a high correla-
tion (r = 0.95 p < 0.001) between T4 levels mea-
sured in the monoclonal antibody assay and those
measured in the conventional antiserum RIA. This
suggests that the monoclonal antibody is directed to-
wards the same antigenic sites on T4 äs the polyclo-
nal antiserum. The relationship found was MCA
(SPAC) T4 = 0.875x (Amerlex T4) + 17.218. The
slope of the regression line was significantly different
from unity (p < 0.001) and the intercept statistically
different from zero (p < 0.001), indicating that the
MCA (SPAC) T4 assay produces higher values than
those of Amerlex T4 throughout most of the assay
ränge. In contrast, T4 levels in low-, medium- and
high-concentration control sera were lower when
measured by the MCA (SPAC) T4 assay than by
Amerlex T4 (tab. 1).
There was very little cross-reaction of TS and rTa in
the Amerlex T4 assay (2.7% and 1.1% respectively)
and T3 with T4 in the MCA (SPAC) assay (0.6%).
However cross-reaction of rTa in the monoclonal T4
assay was high (25.0%). Since, in normal subjects,
rT3 circulated at a concentration <1% than that of
T4 (16), this cross-reaction would be unimportant in
practice.
Recoveries
The Amerlex T4 method gave a mean recovery of
98% (ränge 95-102%) while the MCA (SPAC)
method averaged a recovery of 100% (ränge 91—
110%). As no single recovery was less than 85% or
greater than 115%, the recoveries found for both
methods were acceptable according to the criterion
of Logan (17).
The regression lines calculated for the correlation of
added amount vs expected amount indicated that
there were excellent linear recoveries in the mono-
clonal antibody and conventional antiserum RIA's (r
= 1.00 for both assays). In addition their slopes were
not significantly different from unity nor intercepts
statistically different from zero (slopes and inter-
cepts for Amerlex and MCA (SPAC) T4, respective-
ly, were 1.06-2.43 and 1.05, -2.25). These results
indicate that there is quantitative recovery in both
assays independent of the concentration of T4 to be
measured.
Test of parallelism
Amerlex and MCA (SPAC) T4 methods produced
good linearity on dilution throughout the assay ränge
(r = 1.00 for both assays). The slope of the line for
experimental values vs expected values was not sig-
nificantly different from unity for the Amerlex assay
(slope = 1.00). In contrast the MCA (SPAC) T4 as-
say failed to show parallelism (slope = 0.81, p <
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0.01). The non-parallelism, indicating interference
in the monoclonal antibody assay by factors other
than those which can be clearly identified by their
physiochemical similarity to T4 (10), could explain
the higher MCA (SPAC) T4 values in patient's
serum compared with those determined by the
Amerlex method.
Clinical evaluat ion
Table 2 shows means for FT4 and results for the
MCA (SPAC) and Amerlex T4 kits in six clinical
groups. The percentage of patients in these groups
whose values lie outside reference intervals for FT4
and the two T4 kits is also shown.
Patients with thyroid disease
The mean values for T4 by both methods — äs ex-
pected - were increased (p < 0.001) in hyperthyroi-
dism. In this gfoup one patient (7%) had a normal T4
when measured by Amerlex whereas T4 values as-
sayed by the MCA (SPAC) kit were within the eu-
thyroid ränge in four patients (27%). Amerlex and
MCA (SPAC) T4 values were significantly decreased
(p < 0.001) in hypothyroid patients. These patients
were distinguished with 93% accuracy frorn normal
subjects by the Amerlex T4 kit (tab. 2) whereas only
73% of hypothyroid patients had MCA (SPAC) T4
values below normal Kmits.
Thus T4 values measured by the conventional anti-
body RIA were a slightly more sensitive indicator of
thyroid disease than those assayed by the monoclo·^
nal antibody assay.












































110.7 (0) 115.2 (0)
18.3 23.6
Statistical significance of difference from euthyroid (control)
mean indicated by "p < 0.05; bp < 0.01; <p < 0.001. Numbers in
parentheses are the percentages of patients whose values lie out-
side the reference interval by each measure.
Subjects with increased thyroid Hormone binding ca-
pacity
The concentration of TBG progressively increases
with the duration of pregnancy (18, 19). Therefore
- äs expected - T4 values by both methods were
significantly increased (p < 0.001) äs compared with
the control group in third trimester pregnants. In
these women, more than one-half (55%) of their T4
values by Amerlex were in the hyperthyrqid fange
whilst about a third (35%) of T4 values assayed by
MCA (SPAC) were elevated.
In oral contraceptive users, T4 values by both meth-
ods were increased (p < 0.001), äs a direct conse-
quence of elevated TBG concentrations. Amerlex
and MCA (SPAC) T4 values were elevated in 30%
and 25% of patients on oral contraceptives, respec-
tively.
Therefore, in sera of pregnant women and oral con-
traceptive users, the T4 value was a more appropriate
reflection of TBG concentration, when measured by
the conventional RIA than by the monoclonal anti-
body assay. All 20 patients controlled on thyroxine-
replacement therapy gave normal T4 values by Amer-
lex and MCA (SPAC) methods. Hence concentra-
tions measured by the monoclonal antibody assay
and by the conventional antibody RIA appeared to
be of equivalent välüe in moiiitoring thyroxine-treat-
ed patients.
Correlation beiween FTI and FT4
There were good correlations between FT4 concen-
traäion and FT1 values derived from each of the T4
methods in euthyroid control suBjects and patients
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with thyroid disease (Ainerlex, r = 0.81; p < 0.001
and MCA (SPAC), r = 0.78; p < 0.001). Thus FTI
values derived from either the conventional or the
monoclonal antibody T4 assay, were equally good in
reflecting a patient's true thyroid Status.
Conclusions
In conclusion, the monoclonal antibody used in the
Mallinckrodt (SPAC) T4 had a similar affinity con-
stant to that of a polyclonal antiserum and showed a
clinically insignificant but high cross-reaction with
the structurally-related thyroid hormone, rTa. In ad-
dition, the assay showed good sensitivity, quantita-
tive recoveries and technical simplicity. Furthermore
it demonstrated acceptable diagnostic accuracy, des-
pite the slightly lower sensitivity of the assay äs an
index of thyroid Status in thyroid disease, compared
with that of a polyclonal antibody RIA. Therefore,
in conclusion, a monoclonal antibody T4 assay is suit-
able for use in the clinical laboratory, but it offers no
significant advantages over a RIA employing a con-
ventional polyclonal antiserum.
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